Thrombosis
Conference Coverage
Ticagrelor reversal agent achieves quick hemostasis: REVERSE-IT
The monoclonal antibody bentracimab, which can rapidly reverse ticagrelor, was found effective and safe in an FDA-requested interim analysis of a...
Latest News
Exercise reduces arm and shoulder problems after breast cancer surgery
Study provides the best quality evidence to date in support of early exercise for women at high risk of shoulder problems after breast cancer...
Conference Coverage
PRAGUE-17: LAA closure holds up against DOACs out to 4 years
Most outcomes remained unchanged, but follow-up imaging curtailed by the COVID-19 pandemic leaves an unfortunate gap with regard to late device-...
Conference Coverage
Short DAPT course beneficial after PCI in ‘bi-risk’ patients
MASTER DAPT subgroup analysis supports short antiplatelet course in cases of high bleeding and ischemic risk.
From the Journals
Antithrombotic therapy not warranted in COVID-19 outpatients
In stable patients with COVID-19, use of aspirin or apixaban did not reduce the rate of the composite of all-cause mortality, thromboembolism, MI...
From the Journals
Rivaroxaban’s single daily dose may lead to higher bleeding risk than other DOACs
Corroborating previous studies, Iceland researchers report that rivaroxaban poses the highest risk of GI bleeding, compared with other DOACs.
From the Journals
Circulating post-STEMI ketones elevated, hints at treatment role
Ketone bodies are increased at STEMI, remain elevated after 24 hours of reperfusion, and decline after 4 months.
Latest News
CVST after COVID-19 vaccine: New data confirm high mortality rate
“This is the biggest series, and as an international series, it gives a broader perspective from a larger range of countries.”
From the Journals
Study gives bleeding risk estimates for VTE patients on anticoagulants
New research provides best available estimates of long-term bleeding risk with different anticoagulants, authors say.
Conference Coverage
STOP-DAPT 2 ACS: 1 month of DAPT proves inadequate for patients with recent ACS
Findings from a Japanese trial show 1 month of dual antiplatelet therapy and 11 months of clopidogrel monotherapy is inferior to 12 months of DAPT...
News
Heparin’s COVID-19 benefit greatest in moderately ill patients
A multiplatform trial reported that therapeutic heparin improved outcomes in moderately ill COVID-19 patients but not in critically ill patients...